Leerink Partnrs Estimates PepGen’s Q1 Earnings (NASDAQ:PEPG)

PepGen Inc. (NASDAQ:PEPG) – Research analysts at Leerink Partnrs boosted their Q1 2025 earnings per share estimates for PepGen in a report issued on Monday, February 24th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings per share of ($0.75) for the quarter, up from their prior estimate of ($0.76). The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. Leerink Partnrs also issued estimates for PepGen’s Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.21) EPS and FY2026 earnings at ($2.93) EPS.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.13.

Several other equities research analysts also recently issued reports on the stock. Wedbush cut their price objective on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of PepGen in a research report on Monday. Finally, Bank of America downgraded shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a research report on Monday, December 16th.

PepGen Stock Down 10.5 %

Shares of PEPG stock opened at $1.53 on Wednesday. The firm has a 50 day moving average price of $2.41 and a two-hundred day moving average price of $5.75. The company has a market capitalization of $49.87 million, a PE ratio of -0.51 and a beta of 1.53. PepGen has a 12-month low of $1.16 and a 12-month high of $19.30.

Institutional Trading of PepGen

Institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of PepGen in the fourth quarter worth $26,000. Allspring Global Investments Holdings LLC acquired a new position in shares of PepGen during the third quarter valued at about $95,000. XTX Topco Ltd acquired a new position in shares of PepGen during the third quarter valued at about $130,000. Corton Capital Inc. acquired a new position in shares of PepGen during the fourth quarter valued at about $68,000. Finally, Barclays PLC raised its holdings in shares of PepGen by 318.7% in the 3rd quarter. Barclays PLC now owns 21,971 shares of the company’s stock worth $189,000 after acquiring an additional 16,723 shares during the last quarter. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.